33 results about "Radionuclide therapy" patented technology

Methods and computer readable media are disclosed for ultimately developing a dosimetry plan for a treatment volume irradiated during radiation therapy with a radiation source concentrated internally within a patient or incident from an external beam. The dosimetry plan is available in near"real-time" because of the novel geometric model construction of the treatment volume which in turn allows for rapid calculations to be performed for simulated movements of particles along particle tracks therethrough. The particles are exemplary representations of alpha, beta or gamma emissions emanating from an internal radiation source during various radiotherapies, such as brachytherapy or targeted radionuclide therapy, or they are exemplary representations of high-energy photons, electrons, protons or other ionizing particles incident on the treatment volume from an external source. In a preferred embodiment, a medical image of a treatment volume irradiated during radiotherapy having a plurality of pixels of information is obtained.

A composition and method for targeted use of radionuclide therapy for the treatment of cancer and cancerous tumors, atherosclerotic plaques, joints and other targeted sites. Microparticles, microbubbles, or nanoparticles deliver therapeutic doses of radiation, included radiation from alpha emitting radionuclides, to sites in a patient. The delivery may be targeted by targeting agents linked to the microparticles, microbubbles, or nanoparticles or by the external application of energy, or both.

Brachytherapy radioisotope carrier systems and methodology for providing real-time customized brachytherapy treatment to subjects with tumors difficult to control using conventional radiation therapy techniques. The invention generally relates to devices, methods and kits for providing customized radionuclide treatments, to help cure, slow progression or regrowth, or ameliorate the symptoms associated with tumors.

Brachytherapy radioisotope carrier systems and methodology for providing real-time customized brachytherapy treatment to subjects with tumors difficult to control using conventional radiation therapy techniques. The invention generally relates to devices, methods and kits for providing customized radionuclide treatments, to help cure, slow progression or regrowth, or ameliorate the symptoms associated with tumors.

Brachytherapy radioisotope carrier systems and methodology for providing real-time customized brachytherapy treatment to subjects with tumors difficult to control using conventional radiation therapy techniques. The invention generally relates to devices, methods and kits for providing customized radionuclide treatments, to help cure, slow progression or regrowth, or ameliorate the symptoms associated with tumors.

The present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy and chemical synthesis. More particularly, it concerns a strategy for radiolabeling target ligands. It further concerns methods of using those radiolabeled ligands for imaging, radionuclide therapy and tissue-specific disease imaging.

The invention relates to the preparation of 131I-thyroid stimulating hormone (TSH) and an application thereof, belonging to the field of radionuclide therapeutic drugs. The compound 131I-thyroid stimulating hormone is a radioiodine marker for thyroid stimulating hormone with pathoclisis in vivo acting on thyrocyte. A preparation method of the 131I-thyroid stimulating hormone comprises the following steps of: carrying out iodine 131 marking on the thyroid stimulating hormone by utilizing a chloramine-T method, a peroxide oxidation method or an iodogen method, and introducing radionuclide iodine 131 for treatment into tyrosine residues in thyroid stimulating hormone molecules. The marking rate of the prepared 131I-TSH is 85.9 percent, the radiochemical purity after purification achieves more than 90 percent, and the prepared 131I-TSH can be stored stably for more than one week at room temperature; the 131I-TSH is mainly metabolized through the liver and excreted through the kidneys; the percentage of ID / g of the 131I-TSH in the thyroid gland is not obviously reduced in four hours; and the 131I-TSH can be concentrated in thyroid gland issues sealed by an iodine solution. Concerning low / undifferentiated thyroid tumours incapable of iodine uptake, the 131I-TSH can increase the radioiodine uptake of thyroid gland cancer cells, and the radioiodine 131 can be chosen for treatment.

The invention is directed to modified minigastrin analogs. It further relates to labeling such modified minigastrin analogs with metallic radionuclides. The invention further relates to methods for making such novel modified minigastrin analogs, their labeling with metallic radionuclides and their use in oncology applications as in the targeted diagnostic imaging and staging of CCK-2 / gastrin-R-positive neoplasms in man with SPECT (technetium-99m), or PET (technetium-94m), or eventually in targeted radionuclide therapy (rhenium-188).

The present invention describes chemically modified avidins that have higher permanence in treated tissues compared to wild type avidin. Avidin oxidation is performed by periodate incubation in the presence of the low affinity ligand HABA which, occupying the biotin binding sites, prevents protein denaturation during the oxidation step. Periodate oxidation generates CHO groups from avidin mannose ring opening that, once injected, react with tissue NH2 residues to form stable Schiff's bases. The anchored avidins maintain the ability to bind biotinylated agents endowed of therapeutic activity, like radiolabeled biotins, stem cells and somatic cells, useful for brachytherapies like Intraoperative Avidination Radionuclide Therapy (IART®) or degenerative or genetic diseases.

The invention relates to the field of molecular biology medicine. saRNA molecules of TPO genes are synthesized, the sequence of the saRNA molecules and the sequence SEQ ID NO:1 of the upstream 6,000bp and downstream 1,000bp areas of a TPO gene transcriptional start site are complementary, and low-expression or non-expression TPO genes in tumor cells can be effectively activated. A biological effect of promoting the tumor cells to hold radionuclide 131I is achieved, a novel method and novel molecular targets are provided for combining the gene technology with the radionuclide therapy for targeted therapy of tumors.

A composition and method for targeted use of radionuclide therapy for the treatment of cancer and cancerous tumors, atherosclerotic plaques, joints and other targeted sites. Microparticles, microbubbles, or nanoparticles deliver therapeutic doses of radiation, included radiation from alpha emitting radionuclides, to sites in a patient. The delivery may be targeted by targeting agents linked to the microparticles, microbubbles, or nanoparticles or by the external application of energy, or both.

This invention is to manufacture a kit for preparation of nano-targeted liposome drugs in combined chemotherapy and radionuclide therapy. It is a kit consisting of three components: (1) A 10 ml vial A which contains BMEDA, gluconate acetate, SnCl2. (2) A 10 ml vial B which contains DSPC, cholesterol, DSPE-PEG, and Doxorubicin(DXR) (or Daunorubicin, Vinolbine). (3) A 10 ml vial C which contains 188ReO4− (or 186ReO4−) solution. The procedure of using the kit is as follows: (1) Remove the contents of the 188ReO4− (or 186ReO4−) solution from vial C. (2) Inject the 188ReO4− (or 186ReO4−) solution into the vial A, and the mixtures react in appropriate temperature. (3) Remove the contents of the 188Re-BMEDA (or 186Re-BMEDA) solution from vial A. (4) Inject the 188Re-BMEDA (or 186Re-BMEDA) solution into the vial B, and the mixtures react in appropriate temperature. The reconstituted solution in the vial B is applied to combine bimodality radiochemotherapy for treatment of tumor and ascites.

The present invention describes chemically modified avidins that have higher permanence in treated tissues compared to wild type avidin. Avidin oxidation is performed by periodate incubation in the presence of the low affinity ligand HABA which, occupying the biotin binding sites, prevents protein denaturation during the oxidation step. Periodate oxidation generates CHO groups from avidin mannose ring opening that, once injected, react with tissue NH2 residues to form stable Schiff's bases. The anchored avidins maintain the ability to bind biotinylated agents endowed of therapeutic activity, like radiolabeled biotins, stem cells and somatic cells, useful for brachytherapies like Intraoperative Avidination Radionuclide Therapy (IART®) or degenerative or genetic diseases.

The present invention relates to a metal complex of the general formula M(L)n, wherein each L is independently selected and represents a ligand and at least one L is vitamin B12 (cyanocobalamin) or a derivative thereof bound through the nitrogen atom of its cyanide group to M, which is an element selected from the transition metals, thus, forming a M-NC—[Co] moiety with [Co] representing vitamin B12 without cyanide and wherein n is 1, 2, 3, 4, 5 or 6. The complex can be prepared by mixing a precursor molecule with vitamin B12. The metal complexes can be used for radiodiagnostics, chemotherapy and radionuclide therapy.

A radiopharmaceutical composition is disclosed comprising novel iodometomidate derivatives of formula (I) which bind specifically to adrenal enzymes and which exhibit an improved stability. The compounds of formula (I) are suitable for use in a diagnostic imaging method, e.g. for diagnosis of adrenocortical carcinoma. The compounds of formula (I) are further suitable for use in the treatment of adrenocortical carcinoma, by means of radionuclide therapy.

The present invention relates to a metal complex of the general formula M(L)n, wherein each L is independently selected and represents a ligand and at least one L is vitamin B12 (cyanocobalamin) or a derivative thereof bound through the nitrogen atom of its cyanide group to M, which is an element selected from the transition metals, thus, forming a M-NC-[Co] moiety with [Co] representing vitamin B12 without cyanide and wherein n is 1, 2, 3, 4, 5 or 6. The complex can be prepared by mixing a precursor molecule with vitamin B12. The metal complexes can be used for radiodiagnostics, chemotherapy and radionuclide therapy.

The invention discloses a < 131 > I-HSA-ICG nano-particle as well as a preparation method and application thereof, and belongs to the technical field of nano-drug preparation. HSA is used as a carrier, radioactive < 131 > I is labeled in a neutral environment through a chloramine T method, and ICG is non-covalently bound to < 131 > I-HSA nanoparticles through a stirring reaction, so that the < 131 > I-HSA-ICG nanoparticles are prepared. The < 131 > I-HSA-ICG nanoparticles prepared by the invention not only can be used for local tumor bimodal imaging, but also can be used for simultaneously performing photothermal therapy and radionuclide therapy on human undifferentiated thyroid cancer. The synthesis method of the < 131 > I-HSA-ICG nano-particles is simple, easy to repeat, low in toxicity and effective and remarkable in treatment effect, and a new thought is provided for treatment research of the undifferentiated thyroid cancer.

Methods and compositions for treating, diagnosing and staging cancers, in particular overexpressing the Human Epidermal growth factor Receptor 2 protein (HER2+) given rise to in breast, gastric, gastroesophageal, ovarian, pancreatic cancer and brain tumors, which may be metastatic to the brain or other site. More specifically, the invention provides for Targeted Radionuclide Therapy (TRNT) with a compound of the invention having a peptide that targets the HER2+ cells, a second component for combining metals into complexes through a ring structure (DOTA), and a third radioisotope component, Lu-177 and Ga-68, in which embodiments further include a companion diagnostic, and in which embodiments further include anti-integrin precision medicines for cancers expressing αvβ3 and αvβ5 integrins, HER2+, vascular endothelial growth factor, vitronectin, fibronectin, tenascin, reelin, kindlin and talin. TRNT may be administered alone or in combination with standard-of-care; an immunooncologic and / or chemotherapeutic, adjuvantly or neoadjuvantly.

The compounds used in this method for the treatment of bladder cancer comprise a radioisotope particle emitter, such as alpha- or beta-emitters or low energy gamma-emitters, associated with a chelating agent (for metallic radioisotopes) or other compound (by covalent bond for iodine or other non-metals) selected such that these permit delivery of the radionuclide by an I.V. injection that is then cleared into the bladder by the kidneys. Furthermore, it is expected that these radioisotopes are formulated with customary pharmaceutically-acceptable salts, adjuvants, binders, desiccants, diluents, and excipients.

The present invention is directed to a novel compound of Formula 1 wherein the radiolabeled compound of Formula 1 is capable of being used as a radiotracer in PET imaging of a targeted localized tissue and targeted radionuclide therapy of one or more conditions that may be regulated or normalized via inhibition of transporter such as Pgp, BCRP or MRP I. The novel compounds of Formula 1 can also be used as substrates for binding with one or more ABC transporters. In particular, the present invention aids in diagnosis and therapeutic treatment of MDR disorders in all forms of cancers and neurological disorders of the central nervous system. The present invention further provides methods of preparation of compounds of Formula 1 and novel intermediates used in the preparation of compounds of Formula 1.

The invention relates to a probe capable of reducing radioactive kidney concentration based on an enzyme digestion principle and a preparation method of the probe. The general formula of the probe isas follows: R1 refers to a bifunctional chelating agent group, R2 refers to a side chain residue of hydrophobic amino acid, and R3 refers to a targeting ligand. A radioactive complex of the probe canbe used as a nuclide imaging probe or a radionuclide treatment probe, not only has an excellent imaging or treatment effect when applied to human or animals, but also can remarkably reduce radioactiveconcentration and retention of kidneys, has a very high target / non-target ratio, greatly reduces the radiation dose when being applied to human or animals, is safer and more effective and has extremely high clinical popularization value.

Provided is a process of producing activated particles comprising 188Re-isotopes and / or 186Re-isotopes by irradiating non-volatile and water-insoluble starting particles comprising a rhenium compound with neutrons. Further provided is a process of producing corresponding non-volatile and water-insoluble starting particles. Further provided are respective starting particles and activated particles, respectively, and a composition comprising a plurality of activated particles. The activated particles, and the composition comprising same are suitable for use in radionuclide therapy, and for cosmetic applications.

The invention discloses a chemical composition for target imaging, which is used in the fields of radiation chemistry, nuclear imaging, radionuclide therapy and chemosynthesis and comprises TA2S derivatives which can be conjugated with a therapeutic or diagnostic ligand and can be chelated with metal under certain conditions.

The invention provides a radioactive source delivery device for a nuclide post-loading treatment machine, which includes: a real source driving mechanism, a false source driving mechanism, a source storage lead bag, a source tube, and a source detection mechanism; the peripheral equipment is a source applicator ; Among them, both the real source drive mechanism and the false source drive mechanism include: stepper motor, drive disc, drive belt, four pulleys, steel wire rope, steel wire storage pipeline, micro switch, access guide nozzle, delivery guide nozzle, steel wire Tail detection device, channel obstruction detection device, belt tensioning device; the key point of the present invention is that the radioactive source steel wire rope is always in the storage pipeline, without multiple coils on the driving disc, and the source jamming failure will not occur. Moreover, the invention has the characteristics of safety and reliability, convenient installation of radioactive sources, and simple debugging and maintenance.

A radiopharmaceutical composition is disclosed comprising novel iodometomidate derivatives of formula (I) which bind specifically to adrenal enzymes and which exhibit an improved stability. The compounds of formula (I) are suitable for use in a diagnostic imaging method, e.g. for diagnosis of adrenocortical carcinoma. The compounds of formula (I) are further suitable for use in the treatment of adrenocortical carcinoma, by means of radionuclide therapy.